Company History:

• 2007: ISTO receives patent for its cell expansion process that allows potentially thousands of grafts from one donor.
• 2007: ISTO receives 510(k) clearance for InQu Bone Graft Extender as a bone graft substitute
  
• 2006: ISTO Technologies and Zimmer Holdings, Inc. begin the clinical trial for DeNovo ET.
• 2006: ISTO Technologies and Zimmer Holdings Inc., announce that the U.S. Food and Drug Administration approved ISTO’s Investigational New Drug application for DeNovo ET.
• 2003: Mitchell Seyedin PhD joins the Company as President and Chief Executive Officer. Dr. Seyedin had 24 years experience in medical research, product development and building entrepreneurial companies.
• 2000: ISTO establishes collaborative agreement with Zimmer Inc. for its DeNovo ET product. Zimmer is a globally recognized orthopedic company.